Image by Freepik
A new Yale School of Medicine and Icahn School of Medicine at Mount Sinai study found that people who have experienced brain fog, confusion, pain, and extreme fatigue for months or longer after being infected with COVID-19 have different immune and hormonal responses to the virus.
These different responses may help scientists pinpoint the origins and maybe solutions for the frequently debilitating condition that has impacted millions worldwide. The U.S. estimates 7.5% of SARS-CoV-2 infections develop long-term COVID.
“If you are a doctor doing routine lab work on these patients, you are not going to find these signals,” said Akiko Iwasaki, Sterling Professor of Immunobiology at Yale and co-senior author of the paper.
The findings appeared in Nature on Sept. 25.
The study examined blood samples from 268 persons who had long-term COVID symptoms for an average of one year, had recovered from COVID-19, or had no past infections. The researchers found substantial changes in circulating antibodies and other immune system cells between long-COVID patients and others.
Long-term COVID patients have higher levels of antibodies that combat non-COVID-19 viruses, including Epstein-Barr virus, a human herpesvirus related to many malignancies. These individuals also had significantly reduced cortisol levels, a stress hormone secreted by the adrenal glands.
The scientists say these data indicate fundamental molecular processes related with chronic COVID, but the variety of individual reactions makes creating treatments difficult.
“There is no ‘silver bullet’ for treating long COVID, because it is an illness that infiltrates complex systems such as the immune and hormonal regulation,” said co-senior author David Putrino, a professor of rehabilitation and human performance at Icahn Mount Sinai and director of the Cohen Center for Recovery From Complex Chronic Illness
Iwasaki said the new findings may contribute in the development of novel diagnostics and treatments.
“Once we have more information on these signals, we can start to think about designing the right trials to treat this condition,” she said.
more recommended stories
Alzheimer’s Disease Study Questions Glucosamine SafetyKey Summary New research published in.
WHO: Andes Hantavirus Not a COVID-19-Level ThreatKey Summary Andes hantavirus has drawn.
Genetic Screening Project Launches for Brazilian ParentsKey Summary Brazil is launching the.
CAR T-Cell Therapy Offers Hope for Highly Sensitized PatientsKey Summary Researchers at the University.
Gut Keystone Bacteria: How Diet Shapes Microbiome HealthKey Takeaways Researchers are identifying “gut.
Chronic Liver Disease in Europe Raises Public Health AlarmKey Summary A new report in.
CDC Nutrition Biomarkers Study Offers Public Health InsightsKey Points The upcoming CDC Nutrition.
Macrophages Attack Live Melanoma Cells in Real TimeKey Takeaways Researchers at the Garvan.
Facial Micromovements Linked to Accurate Pain DetectionKey Takeaways Researchers at Rutgers University–New.
Nicotine Pouches Under Scrutiny in New WHO WarningKey Takeaways The World Health Organization.
Leave a Comment